Delving into the Latest Updates on DCVAC/OvCa with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, Dendritic cell vaccine

Synonyms

Dendritic cell vaccine/Ovarian cancer

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Peritoneal Neoplasms

Inactive Indication

CarcinomaFallopian Tube CarcinomaOvarian Cancer

Originator Organization

Excoso as

Active Organization

Excoso as

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.

Start Date19 Apr 2021

Sponsor / Collaborator

Peking University Third Hospital

[+1]

NCT03657966 / CompletedPhase 2

An Open-label, Single-group, Multi-center, Phase II Clinical Trial Evaluating the Effect of Maintenance DCVAC/OvCa After Standard-of-care Therapy in Women With First Relapse of Platinum-sensitive Epithelial Ovarian Cancer

The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial ovarian carcinoma who experienced relapse more than 6 months after complete remission of first line platinum-based chemotherapy (platinum sensitive ovarian cancer)

Start Date23 Nov 2017

Sponsor / Collaborator

Excoso as

100 Clinical Results associated with DCVAC/OvCa

Login to view more data

100 Translational Medicine associated with DCVAC/OvCa

Login to view more data

100 Patents (Medical) associated with DCVAC/OvCa

Login to view more data

2

Literatures (Medical) associated with DCVAC/OvCa

01 Jan 2012·Oncology LettersQ4 · MEDICINE

Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells

Q4 · MEDICINE

Article

Author: Enrique T. Ona ; Gloria R. Cristal-Luna ; Romulo de Villa ; Oscar Q. Canlas ; Josephine B. Laguatan ; Aileen Riego-Javier ; Samuel D. Bernal ; Eunice R. Batac

Hematopoietic stem cells collected by leukapheresis of a patient with metastatic ovarian carcinoma (OVCA) were induced into dendritic cell (DC) differentiation and fused with liposomal constructs of autologous and allogeneic ovarian carcinoma antigens (DC-OVCA). The proliferation of autologous T cells induced by DCs was determined by [(3)H]-thymidine uptake. Maximal T-cell proliferation was observed in co-cultures of DCs fused with liposomal OVCA constructs compared with intact autologous OVCA cells. The combination of autologous and allogeneic liposomal OVCA constructs induced greater T-cell proliferation than either alone. The cytotoxicity of DC-activated T cells against various target cells were analyzed by a (51)Cr-release assay. The combination of autologous and allogeneic liposomal OVCA constructs showed the highest stimulation of T cell-mediated cytotoxicity against OVCA cells, but had minimal cytotoxicity against normal fibroblasts or leukemia cells. The liposomal preparations of DC-OVCA were injected monthly into a patient with metastatic ovarian carcinoma whose tumors progressed following multiple courses of chemotherapy. DCs analyzed from the patient post-immunization showed 2- to 3-fold greater OVCA cytotoxicity compared to pre-immunization DCs. Immunoblots using the patient's serum showed reactivity with a number of proteins from ovarian cancer extracts, but not in normal fibroblasts and breast cancer. Following the DC-OVCA treatment, the metastatic lesions progressively decreased in size to the point of being undetectable by serial CAT scans. Seven years following the initial diagnosis, the patient continues to be free of cancer. This report described the anticancer immune reactivity and anti-tumor response induced by DCs sensitized with liposomal constructs of OVCA antigens. Immune cell therapy may therefore be a useful adjunct to surgery and chemotherapy for the treatment of ovarian cancer.

01 Jan 2000·Immunological InvestigationsQ3 · MEDICINE

Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading

Q3 · MEDICINE

Article

Author: Theresa Whiteside ; Hassane Zarour ; Elena Ranieri ; Michael T. Lotze ; John M. Kirkwood ; Lisa S. Kierstead ; Walter J. Storkus

A review with 19 references is presented regarding dendritic cell/peptide cancer vaccines.Clin. studies have shown that peptide-based vaccines may result in a broadly-reactive anti-tumor T effector cell repertoire that may correlate with tumor regression and preclude the progression or recurrence of simple tumor antigen-loss variants.

100 Deals associated with DCVAC/OvCa

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peritoneal Neoplasms	Phase 3	-	Excoso as	-
Carcinoma	Preclinical	-	Excoso as	02 Apr 2019
Fallopian Tube Carcinoma	Preclinical	-	Excoso as	02 Apr 2019
Ovarian Cancer	Preclinical	-	Excoso as	02 Apr 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02107950 (SOV02, Pubmed) Manual	Phase 2	Platinum-Sensitive Ovarian Carcinoma Second line	71	carboplatin+gemcitabine+DCVAC/OvCa	(mcubekzceu): HR = 0.73 (95% CI, 0.42 - 1.28), P-Value = 0.274 View more	Negative	01 Sep 2021
				carboplatin+gemcitabine